1. Introduction {#sec1}
===============

Currently, percutaneous coronary intervention (PCI) is widely used around the world to treat coronary artery disease (CAD) and has significantly reduced mortality in patients with acute coronary syndromes \[[@B1]\]. However, the incidence rate of in-stent restenosis (ISR) is still approximately 10%, even accounting for the introduction of drug-eluting stents (DES) \[[@B2]\], and reaches as high as 40%--50% in patients with multivessel involvement \[[@B3]\]. ISR therefore inflicts a heavy burden on both the lives of patients with CAD and the economy and remains a challenge to the implantation of PCI and CAD prognoses.

In traditional Chinese medicine (TCM), the typical symptoms of ISR, such as chest pain and chest tightness, are referred to as "Xiongbi" \[[@B4]\]. TCM presents mature theories and is supported by abundant clinical experience for treating "Xiongbi". In recent years, the efficacy and safety of TCM in ISR has been widely studied with remarkable results. Studies have shown that TCM not only clearly alleviates the typical symptoms of ISR but also improves its long-term prognosis, suggesting that TCM may lead to promising applications for the treatment of ISR.

Previous reviews focused on this issue were published in 2008 \[[@B5]\], 2012 \[[@B6]\], and 2014 \[[@B7]\]. The first two of these studies were systematic reviews (SRs), and the latter was a meta-analysis. They explored the effects of many types of PCI and included studies with small sample sizes (fewer than 30 cases) and that explored a single TCM herb. In addition, a presearch showed that, in the 3 years since 2014, more studies have supported the efficacy and safety of oral compound Chinese medicines (CCMs) in ISR. In this SR, we applied more rigorous inclusion and exclusion criteria and aimed to explore whether oral CCM plus routine western medicine (RWM) is effective and safe for treating ISR after stent implantation. We use CCM because it has wider applications in clinical practice and conforms better to TCM theory.

2. Methods {#sec2}
==========

This SR was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement \[[@B8]\] and the Cochrane Handbook \[[@B9]\] Systematic review and is registered at PROSPERO with the registration number CRD42017075368 (https://www.crd.york.ac.uk/PROSPERO).

2.1. Search Strategy {#sec2.1}
--------------------

A comprehensive search of 7 medical databases, including the PubMed, EMBASE, Cochrane Library, China National Knowledge Infrastructure (CNKI), Chinese Scientific Journals (VIP), Wanfang, and Chinese Biomedical (CBM) databases, was conducted through April 2017 without a language restriction. We performed the search using individually or combined Mesh terms for all fields relating to the patients (coronary heart disease and coronary artery disease) and interventions (traditional Chinese medicine, Chinese herbal medicine, compound Chinese medicine, Chinese prepared medicine, Chinese herbal formula, and Chinese herbs) of interest. All titles/subjects related to the outcome (in-stent restenosis) were searched. When searching Chinese databases, the above terms were searched in Chinese.

2.2. Inclusion Criteria {#sec2.2}
-----------------------

Only randomized controlled trials (RCTs) were included. We focused on trials with participants diagnosed with major angiographic criteria-documented \[[@B10]\] CAD who were eligible for stent implantation (with either bare metal stents or drug-eluting stents) regardless of their gender, age, disease course, comorbidity, and ethnic origin. The baseline characteristics of each study were consistent. The interventional treatment was any oral CCM plus RWM administered for at least 1 month regardless of dosage. The control group was treated with the same RWM or with a CM placebo plus the same RWM. "CCM" included Chinese prepared medicines or Chinese herbal formulas. The compositions of the CCM were detailed. Our primary outcomes were restenosis occurring within at least 6 months of follow-up. Coronary in-stent restenosis is classically defined as the angiographic detection of a recurrent stenosis with a diameter greater than 50% at the stent segment or the 5 mm segments adjacent to it (in-segment restenosis). The drop-out rate for coronary angiography (CA) review was required to be lower than 20%. Each included study was required to report the primary outcome. Secondary outcomes could be major adverse cardiac events (MACE), including recurrent angina, myocardial infarction, revascularization, and cardiac death. Only secondary outcomes that improved in equal to or more than 50% of cases were considered responses. In addition, adverse reactions were considered as a primary safety outcome. When there were several follow-up points, only the last one was considered.

2.3. Exclusion Criteria {#sec2.3}
-----------------------

Studies with a small sample study (less than 30 cases), duplicate reports, and pilot studies were excluded. Any trial that failed to satisfy the inclusion criteria or for which required data were unavailable was excluded.

2.4. Data Extraction {#sec2.4}
--------------------

Two reviewers (Jinjin Lu and Yan Li) independently extracted the data using a standardized extraction form. Disagreements were resolved by census or consultation with a third reviewer (Wenhao Jia). The following items were extracted: study name, year of publication, sample size, details of the trial design (i.e., randomization, allocation concealment, and blinding), eligibility criteria, general characteristics of patients, details of intervention and control therapies, details related to outcomes, details related to drop-outs, and other information that may help detect bias.

2.5. Quality Assessment {#sec2.5}
-----------------------

Two reviewers (Xiaoyun Cui and Kun Zhou) independently assessed the methodological quality of the included studies using the Cochrane Collaboration\'s tool \[[@B11]\], which is a domain-based evaluation tool used to generate a "risk of bias" table for each study. Any disagreement was resolved by consensus or consultation with a third reviewer (Yanchao Huang). The domains used for assessment were sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective outcome reporting (reporting bias), and other potential sources of bias (e.g., early termination, contamination, and conflict of interest). Because it is difficult to blind participants in studies of Chinese herbal medicines, performance bias was likely present in all trials. With regard to the objective outcomes adopted in this SR, such as ISR and MACE, performance bias and detection bias might not be as important, and we therefore summarized these trials as low-risk. In addition, with regard to selective outcomes, this domain was ranked as "low-risk" unless the outcomes were critical to our issue.

2.6. Data Analysis {#sec2.6}
------------------

Data synthesis and analysis were performed with RevMan software 5.3 and STATA 12.0 software (StataCorp LP, College Station, TX) \[[@B9]\]. Dichotomous data were measured as relative risk (RR), while continuous data were measured as the mean difference (MD), both with corresponding 95% confidence intervals (CIs). Heterogeneity across trials was measured with the Cochran *Q* test and is presented as *I*^2^ statistics. Only trials with *I*^2^ lower than 85% were used for the meta-analysis, and the characteristics of the included trials were similar. A fixed effect model was used if *I*^2^ was lower than 25%. Otherwise, a random effect model was applied under the assumption that any heterogeneity was readily explainable. Furthermore, funnel plot and Egger\'s test were performed to detect heterogeneity and publication bias, respectively, if sufficient sources were available. A 2-tailed *P* value less than 0.05 was considered significant. A sensitivity analysis was conducted to assess the stability of the results.

3. Results {#sec3}
==========

3.1. Study Identification {#sec3.1}
-------------------------

All eligible studies were screened and identified ([Figure 1](#fig1){ref-type="fig"}). A total of 2198 records were retrieved. Of these, full-text evaluations were conducted on 114 studies. In all, 74 of these 114 studies were excluded for the following reasons: non-RCT or quasi-RCT (*n* = 9); follow-up \< 6 months (*n* = 4); drop-outs from CA review \> 20% or failure to report the prespecified primary outcome (*n* = 42); failure to report the composition of the CCM (*n* = 3); control group consisted of a CM injection or another CCM (*n* = 2); review (*n* = 3); treatment duration \< 1 month or unclear (*n* = 2); unavailable data (*n* = 3); patients without stent implantation (*n* = 3); small study sample size (*n* = 2); and unclear baseline characteristics (*n* = 1). Finally, a total of 40 RCTs with a total of 4536 patients were included in this SR \[[@B14]--[@B53]\].

3.2. Characteristics of Included RCTs {#sec3.2}
-------------------------------------

All studies were conducted in China from 2010 to 2017. The average age of the patients ranged from 52.93 to 69.27 years old. Most trials had more males than females. The diagnostic criteria for CAD were mainly based on CA criteria or the Nomenclature and Diagnostic Criteria for Ischemic Heart Disease (World Health Organization, WHO) \[[@B54]\]. All patients successfully underwent stent implantation. The distributions of baseline characteristics were basically the same in each group. Four trials \[[@B27], [@B28], [@B38], [@B51]\] were double-blinded, and, in three trials, the control group used a CM placebo plus RWM \[[@B21], [@B27], [@B28]\]. The remaining trials were designed to compare a CCM plus RWM group to a group treated with same RWM alone. Of the 40 studies, 20 used a decoction, 1 used an oral liquid, 2 used granules, 4 used pills, 12 used capsules, and 1 used tablets. RWM mainly consisted of aspirin, Clopidogrel, angiotensin-converting inhibitor (ACEI)/angiotensin II receptor blocker (ARB), beta-blockers, and statins. The dosage and types of RWM were prescribed according to the recommendations of Chinese Society of Cardiology Guideline \[[@B10]\]. Overall, 33 kinds of CCM were used, and the treatment courses ranged from 3 to 12 months with a follow-up time of 6 to 18 months. For outcomes, ISR was assessed by computed tomography angiography (CTA) or CA in all trials; adverse reactions caused by CCMs were reported in 11 studies but were significant in only 2 studies \[[@B28], [@B40]\]; MACE were reported in 12 studies and included recurrent angina (*n* = 12), myocardial infarction (*n* = 3), revascularization (*n* = 2), and cardiac death (*n* = 5) (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}).

3.3. Methodological Quality of Included RCTs {#sec3.3}
--------------------------------------------

Of the 40 included studies, 13 were randomized by random number tables or SPSS software. The other 27 studies used the phrase "randomly allocating" but did not describe the method of randomization. Only 1 trial reported allocation concealment as "by sealed, opaque envelopes". Participants or outcome assessors were blinded in only 4 trials. All studies reported the primary outcome and clearly described the data collection methods, and we therefore believed that they were free from selective reporting bias. According to the criteria we prespecified, as shown in the Quality Assessment section, we judged the performance bias and detection bias of these studies to be low-risk. In conclusion, the overall methodological quality of the 40 trials was rated as low-risk. The details of this analysis are shown in [Figure 2](#fig2){ref-type="fig"}. The mean score for the RCTs included in this analysis was 5.15 ([Table 3](#tab3){ref-type="table"}).

3.4. Primary Outcomes {#sec3.4}
---------------------

### 3.4.1. In-Stent Restenosis {#sec3.4.1}

Three studies provided data for the number of ISR (NoR), and the pooled estimates showed that, in patients with CAD, NoR was lower for CCM plus RWM than for RWM alone (RR 0.24, 95% CI 0.10 to 0.57, *P* = 0.001; *I*^2^ = 0%, *P* = 0.81) after 6 months of follow-up. In all, 34 studies provided data on the number of cases of ISR that had a follow-up time of 6 to 18 months. The rate of ISR was obviously lower in the CCM plus RWM group than in the group treated with the same RWM alone (RR 0.44, 95% CI 0.37 to 0.53, *P* \< 0.00001; *I*^2^ = 0%, *P* = 0.95). A meta-analysis of an additional 3 studies also showed that CCM plus RWM exerted a beneficial effect on the rate of ISR when CM placebo plus RWM was used as the control intervention with a 6- to 12-month follow-up (RR 0.34, 95% CI 0.20 to 0.57, *P* \< 0.0001; *I*^2^ = 0%, *P* = 0.95). In addition, we evaluated these 34 studies to detect publication bias. The funnel plot was asymmetrical, indicating publication bias. Because funnel plot is used as a qualitative method to detect the publication bias of an article, we also used Egger\'s method to detect publication bias, and the results again implied the presence of publication bias (*P* = 0.00 \< 0.05). The details of these analyses are shown in Figures [3](#fig3){ref-type="fig"}[](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"} and [Table 4](#tab4){ref-type="table"}.

### 3.4.2. Subgroup Analysis {#sec3.4.2}

Different types of Western medicine were used among the 34 studies, and we therefore performed a subgroup analysis. In 25 studies, a better benefit was exerted on ISR by CCM plus RWM (DAPT, DAPT + Statin, DAPT + *β*-blocker + Statin, Nitrates + DAPT + ACEI/ARB + *β*-blocker + Statin, Nitrates + DAPT + ACEI/ARB + *β*-blocker + Statin + CCB) than the RWM alone. In 4 studies, there was no significant difference between the CCM plus RWM (Nitrates + DAPT + Statin, Nitrates + DAPT + ACEI/ARB + *β*-blocker + Statin) group and the RWM group ([Table 5](#tab5){ref-type="table"} and [Figure 6](#fig6){ref-type="fig"}).

Difference in the dosage forms of drugs (e.g., decoction, granules, pills, capsules, and tablets) might impact results, and we therefore carried out a subgroup analysis. A pooled estimate of cases of ISR showed that there was a significant difference between the decoction plus RWM and RWM alone groups in 18 studies (RR 0.28, 95% CI = 0.20 to 0.38, *P* \< 0.00001; *I*^2^ = 0%, *P* = 0.97). No additional benefit was exerted in ISR in the granules plus RWM group than in the RWM alone group (RR 0.39, 95% CI 0.13 to 1.21, *P* = 0.10; *I*^2^ = 0%, *P* = 0.46). A meta-analysis of another 3 studies also showed that there was no significant difference between the pills plus RWM group and the RWM alone group (RR 0.59, 95% CI 0.34 to 1.01, *P* = 0.60; *I*^2^ = 0%, *P* = 0.89). There were significantly fewer cases of ISR in the capsules plus RWM group than in the group treated with the same RWM alone (RR 0.49, 95% CI 0.36 to 0.67, *P* \< 0.00001; *I*^2^ = 0%, *P* = 0.97). The details of these analyses are shown in [Table 6](#tab6){ref-type="table"} and [Figure 7](#fig7){ref-type="fig"}.

The association between the use of CCM plus RWM and RWM alone remained significant after the sensitivity analysis excluding studies with low quality score (quality score  ⩽ 4) with a pooled RR of 0.41 (95% CI, 0.34--0.50). ([Figure 8](#fig8){ref-type="fig"}).

### 3.4.3. Adverse Reactions {#sec3.4.3}

Only 2 studies reported the details of adverse reactions related to CCM, including hepatic dysfunction, gingival bleeding, diarrhoea, stomach discomfort, flushing, dizziness, and headache. More adverse reactions were reported in patients treated with a Huoxue yiqi decoction and a Shenshao decoction, but most of these reactions were not severe and disappeared without special treatment. There was no significant difference in adverse reactions between the CCM plus RWM and RWM alone groups ([Table 7](#tab7){ref-type="table"} and [Figure 9](#fig9){ref-type="fig"}).

3.5. Secondary Outcomes {#sec3.5}
-----------------------

### 3.5.1. Major Adverse Cardiac Events ([Table 8](#tab8){ref-type="table"}) {#sec3.5.1}

*Revascularization.* Revascularization was reported in 3 studies, in which 308 patients were treated with 3 different CCMs, including Anxin granules, Shexiang baoxin pills, and a Huoxue yiqi tongmai decoction. After 6--18 months of follow-up, the rate of revascularization was not significantly different between the CCM plus RWM and the RWM alone groups (RR 0.33, 95% CI 0.07 to 1.62, *P* = 0.17; *I*^2^ = 0%, *P* = 0.89) ([Figure 10](#fig10){ref-type="fig"}).

*Myocardial Infarction.* Myocardial infarction (MI) was reported in 5 studies, in which 783 patients were treated with 4 different CCMs, including Anxin granules, Shexiang baoxin pills, Tongxinluo capsules, and a Huoxue yiqi tongmai decoction. During approximately 6--18 months of follow-up, no significant difference was found between the CCM plus RWM group and the RWM alone group (RR 0.33, 95% CI 0.07 to 1.62, *P* = 0.17; *I*^2^ = 0%, *P* = 0.89). A meta-analysis of the other 2 studies also showed that there was no significant difference between the CCM plus RWM group and the CM placebo plus RWM group (RR 0.42, 95% CI 0.11 to 1.60, *P* = 0.20; *I*^2^ = 0%, *P* = 0.91) after 6 months of follow-up ([Figure 11](#fig11){ref-type="fig"}).

*Cardiac Mortality.* In 5 studies of 4 kinds of CCM, 461 patients were included in the treatment group, and 460 patients were included in the control group. Cardiac death was recorded as a measure of effect during a 12--18-month follow-up period. No cardiac deaths occurred in any of the groups in three of the studies or in the experimental group in the other 2 studies. A pooled estimate of cardiac deaths showed that there was no significant difference between the CCM plus RWM and RWM alone groups in the latter two studies (RR 0.25, 95% CI = 0.03 to 2.21; *P* = 0.21; *I*^2^ = 0%, *P* = 0.82) ([Figure 12](#fig12){ref-type="fig"}).

*Recurrent Angina.* Recurrent angina was reported in 11 studies involving 1570 patients. During a 6--18-month follow-up period, the rate of recurrent angina was significantly lower in the CCM plus RWM group than in the groups treated with the same RWM alone (RR 0.50, 95% CI 0.38 to 0.65, *P* \< 0.00001; *I*^2^ = 0%, *P* = 0.84) or with a CM placebo plus the same RWM (RR 0.32, 95% CI 0.19 to 0.54, *P* \< 0.00001; *I*^2^ = 30%, *P* = 0.23) ([Figure 13](#fig13){ref-type="fig"}).

*Angiographic Measurements.* Follow-up angiography performed in patients with ISR at 6--12 months after the index PCI in 7 studies that evaluated 4 Chinese Herbal Medicines (CHMs) in 1917 patients. Baseline information showed that the mean minimal luminal diameter (MLD) before and immediately after the index PCI and the gain in luminal diameter following stent placement were comparable between groups.

MLD is defined as the smallest diameter in the treated lesion area \[[@B55]\] and was reported in 5 studies ([Table 9](#tab9){ref-type="table"}). MLD was significantly better in the CCM plus RWM group than in the CM placebo plus RWM when patients were treated with Tongxinluo capsules (MD~WANG\ XD2010~ 1.27 mm, 95% CI 1.01 to 1.53 mm; MD~YANG\ TL2016~ = 0.35 mm, 95% CI 0.27 to 0.43 mm) and in the CCM plus RWM group than in the group treated with the same RWM alone when a Huoxue yiqi tongmai decoction was evaluated (MD~WANG\ X2016~ 0.42 mm, 95% CI 0.35 to 0.49 mm). There was no significant difference between the groups in the studies evaluating Shenshao oral lotion (MD~ZHANG\ Q2016~ = 0.02 mm, 95% CI −0.02 to 0.06 mm). The Tongxinluo capsule plus RWM did not improve MLD when patients were compared to those treated with the same RWM alone (MD~DENG\ XD2013~ = −1.61 mm, 95% CI −1.93 to −1.29 mm).

The primary angiographic endpoint was late lumen loss (LLL) after 6 to 12 months. LLL was evaluated by determining the difference between the minimum lumen diameter after the procedure and at follow-up using quantitative coronary angiography \[[@B56]\]. LLL was measured in 4 studies of 3 CHMs after 6 and 12 months of follow-up ([Table 10](#tab10){ref-type="table"}). There was a significant difference between the CHM plus RWM group and the control group treated with the same RWM alone when the CHM being tested was Tongxinluo capsules (MD~LU\ HW2014~ = −0.36 mm, 95% CI −0.42 to −0.30 mm), a Xinmai futong decoction (MD~ZHANG\ PF2014~ = −0.3 mm, 95% CI −0.41 to −0.19 mm) and a Shenshao oral lotion (MD~ZHANG\ Q2013~ = −0.05 mm, 95% CI −0.09 to −0.01 mm). Finally, LLL was lower in the RWM plus Tongxinluo capsule group than in the group treated with the same RWM plus placebo (MD~YANGN\ TL2016~ = −0.24 mm, 95% CI −0.28 to −0.20 mm).

In this SR, 40 studies involving 4536 CAD patients who underwent stent implantation were identified. All studies were RCTs. Approximately 75% of the studies were performed in the last five years. A domain-based evaluation showed that the mean score of the included RCTs was 5.15. Of the included studies, three were designed to compare a CCM plus RWM versus a CM placebo plus the same RWM, and 37 studies were designed to compare a CCM plus RWM versus the same RWM alone.

In this SR, all studies assessed ISR using CTA or CA. A three subgroup meta-analysis of 33 CCM plus RWM groups showed that they produced an absolute decrease in the ISR rate. Given the low risk of bias (demonstrated by analyses of methodological quality and publication bias), the following robust conclusion can be drawn: CCM plus RWM reduces ISR. Furthermore, there was no significant difference in adverse reactions between the CCM plus RWM and RWM alone groups in 2 of the studies, potentially indicating that CCM plus RWM is a safe treatment. However, further observations are needed. An Egger\'s linear regression test was performed to statistically assess funnel plot asymmetry and publication bias. Substantially more studies in the literature have positive than negative results, and this produced so-called publication bias.

With regard to secondary outcomes, we concluded that CCM plus RWM did not exert a benefit against revascularization, MI and cardiac mortality during a 6--18-month follow-up period after stent implantation. This finding may be attributed to the limited number of patients and the short follow-up times reported in the studies. However, 11 studies explored CCMs plus RWMs, and recurrent angina was significantly reduced by this treatment during the 6--18-month follow-up period. This may indicate that treatment with a CCM plus RWM exerts a better effect on symptom improvement. Some studies have concluded that a major determinant of the restenosis rate is the final MLD after all interventions \[[@B57]\]. MLD can be evaluated as a continuous end point from 6 to 9 months after intervention and is precisely associated with stable long-term results in the treated coronary segment \[[@B58]\]. In addition, LLL is monotonically correlated with the probability of restenosis and, when evaluated, is a more efficient estimate of restenosis progress in this era of lower binary restenosis rates \[[@B56]\]. Hence, MLD and LLL are two major determinants of the restenosis rate. In this SR, 7 studies that evaluated 4 CHMs reported MLD and LLL. Although pooled results were not available for either MLD or LLL because there was high heterogeneity (*I*^2^ = 97% or *I*^2^ = 99%), in most of the studies, CCM plus RWM exerted significant beneficial effects.

Specifically, Tongxinluo capsules appeared to markedly reduce the rates of ISR, recurrent angina, and LLL and improve MLD. Qiwei sanxiong decoction \[[@B39]\] appeared to markedly reduce the rates of ISR and recurrent angina. Yiqi huoxue huayu decoction \[[@B26]\], Yiqi huayu decoction \[[@B45]\], Yixin tongmai decoction \[[@B24]\], and Yiqi tongluo huatan decoction \[[@B18]\] each provided significant benefits by reducing the rate of ISR. Qishen yiqi droplets \[[@B37]\] exerted significant benefits by reducing recurrent angina. Most of the above-described CCMs are meant to supplement Qi and activate the blood. Their main ingredients are Huangqi (astragalus), Renshen (Panax), Shaoyao (peony), Danshen (salvia), and Chuanxiong (tetramethylpyrazine).

The pathogenesis of restenosis is not yet fully understood. However, it is generally accepted that when a stent causes injury to a coronary artery, it triggers a series of inflammatory reactions that result in the migration and proliferation of vascular smooth muscle cells (SMCs) within the vessel lumen and neointimal hyperplasia. In TCM, CAD is thought to be a result of "Qi deficiency and Blood Stasis". The severity of Blood Stasis syndrome is significantly correlated with the complexity of coronary lesions and the degree of stenosis and is an important factor affecting the occurrence of restenosis after PCI \[[@B59]\]. Many studies have demonstrated that Astragalus \[[@B60]\], salvia \[[@B61]\], tetramethylpyrazine \[[@B62]\], and Chuangxingol and paeoniflorin \[[@B63]\], which are main ingredients in TCM, play effective anti-inflammatory roles and inhibit SMC proliferation and migration. This may be the mechanism by which the above-mentioned CCMs prevent and treat restenosis.

Ideally, RCTs should adhere to known research design standards. In our examination of these studies, we did not have access to enough details related to these characteristics, although the baselines were comparable between comparison groups in the included studies. Details about randomization methodology were also lacking. In the 40 studies we reviewed, 11 reported that they implemented randomization using a random number table or a computer random number generator, such as SPSS software, and only 1 mentioned using sealed, opaque envelope concealment. Participants or outcome assessors were blinded in only 4 of the trials. In addition, studies that involve therapeutic trials should also report the rates of adverse reactions regardless of whether or not they occur. Reporting of adverse reactions is very important for evaluating the safety of interventional measures even though there is no guarantee that the adverse reactions were related to the interventional measure. Subgroup analyses showed that different types of Western medicines and drug forms affected outcomes. Furthermore, most of the 40 studies failed to mention the type of stent that was deployed (i.e., whether it was a bare metal stent or a drug-eluting stent). Therefore, the difference in the curative effects observed between the CCM plus RWM and control groups is uncertain, and there is bias in our results. In our review, only 11 of the 40 included trials reported adverse reactions, rendering it difficult to systematically evaluate the safety of the evaluated CCMs in ISR. Future research on these topics will help to clarify the effectiveness and safety of CCMs in ISR.

4. Conclusions {#sec4}
==============

Based on the results of this SR, we conclude combining RWM with CCMs may provide moderate efficacy in preventing ISR following PCI with stent placement. This is despite the fact that our investigation revealed the potential presence of bias in the identified studies. CCMs used to supplement Qi and activate the blood are suggested for preventing and treating restenosis. In addition, additional experimental studies should explore the mechanisms by which the main ingredients in CCM act to supplement Qi or activating the blood to prevent and treat restenosis. Future rigorously designed RCTs that explore CCM plus RWM therapies aimed at preventing post-PCI ISR should adhere to established design standards to overcome the limitations presented in this review. In particular, they should ensure adequate concealment of allocation and blinding of primary outcomes assessors.
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###### 

Baseline characteristics of included patients.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author,\        No. of patients\   Age, mean\                     Gender, M/F, N.   Co-morbidities, N.\     Lesion site,\   Lesion number,\   Stent number,\            CAD diagnostic guidelines
  Year            (EG/CG)            (SD/range), EG/CG, year                          EG/CG                   EG/CG           EG/CG             EG/CG                     
  --------------- ------------------ ------------------------------ ----------------- ----------------------- --------------- ----------------- ------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  DAI GF 2017     117 (57/60)        63.5 (9.82)\                   E: 36/21\         HTN: 40/41\             LMCA: 4/3\      DBL: 15/16\       109/112                   CA
                                     65.07/(8.99)                   C39/21            DM: 33/34\              LAD: 12/13\     TBL: 4/5\                                   
                                                                                      Dyslipidaemia: 49/51    LCX: 9/10\      MBL: 3/2                                    
                                                                                                              RAC: 10/11                                                  

                                                                                                                                                                          

  ZHANG RZ 2017   138 (70/68)        59.4 (8.5)/57.3 (6.4)          E: 41/29\         HTN: 14/13\             NR              NR                NR                        2007: Guideline for Percutaneous Coronary Intervention (CSC)
                                                                    C: 40/28          DM: 10/9\                                                                           
                                                                                      Hyperlipidemia: 12/10                                                               

                                                                                                                                                                          

  WANG KL 2016    62 (32/30)         58.93 (5.52)/60.43 (5.39)      E: 22/10\         HTN: 25/23\             NR              SBL: 9/8\         1.83 ± 0.58/1.98 ± 0.70   CA
                                                                    C: 16/14          DM: 8/9\                                TBL: 17/15\                                 
                                                                                      Hyperlipidemia: 11/13                   TBL: 6/8                                    

                                                                                                                                                                          

  GONG XY 2016    92 (46/46)         57.8 (1.9)/57.5 (2.1)          E: 21/25\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 20/26                                                                                              

                                                                                                                                                                          

  TANG YY 2016    64 (32/32)         52.32 (4.12)/53.53 (4.55)      E: 20/12\         HTN: 20/19\             NR              NR                NR                        CA
                                                                    C: 22/10          DM: 19/17\                                                                          
                                                                                      Hyperlipidemia: 25/24                                                               

                                                                                                                                                                          

  ZHOU JC 2016    68 (34/34)         NR                             NR                NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

                                                                                                                                                                          

  ZHU HB 2016     64 (32/32)         61.5 (5.5)/60.5 (5.8)          E: 19/13\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 18/14                                                                                              

                                                                                                                                                                          

  XIAO NH 2016    120 (60/60)        63.15 (9.45)/63.83 (9.50)      E: 40/20\         HTN: 44/43\             NR              SBL: 18/19\       137/150                   CA
                                                                    C: 39/21          DM: 14/18                               TBL: 20/19\                                 
                                                                                                                              TBL: 22/22                                  

  REN DD 2016     60 (30/30)         55.4 (9.78)/55.76 (9.25)       E: 16/14\         HTN: 14/13\             NR              SBL: 16/17\       48/47                     CA
                                                                    C: 18/12          DM: 4/5                                 TBL: 10/9\                                  
                                                                                                                              TBL: 4/4                                    

                                                                                                                                                                          

  LI QZ 2016      68 (34/34)         60.2 (4.3)/61.3 (5.2)          E: 20/14\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 19/15                                                                                              

                                                                                                                                                                          

  SUN QY 2016     88 (44/44)         63.1 (3.2)/62.5 (2.6)          E: 29/15\         HTN: 19/18\             NR              NR                NR                        CA
                                                                    C: 28/16          DM: 10/9\                                                                           
                                                                                      Hyperlipidemia: 13/14                                                               

                                                                                                                                                                          

  XU MT 2016      72 (36/36)         58.2 (4.5)/60.5 (10.5)         E: 21/15\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 20/15                                                                                              

                                                                                                                                                                          

  MENG XL 2016    60 (30/30)         60 (46\~72)/61.5 (49\~73)      E: 16/14\         HTN: 12/10\             NR              NR                NR                        *⟪*Internal medicine*⟫*
                                                                    C: 13/17          DM: 5/5\                                                                            
                                                                                      Arrhythmia: 8/9                                                                     

                                                                                                                                                                          

  YANG TL 2016    343 (172/171)      57.93 (9.77)/58.63 (10.27)     E: 137/35\        HTN: 105/102\           LMCA: 6/7\      SBL: 66/69\       301/298                   CA
                                                                    C: 134/37         DM: 172/171             LAD: 117/111\   DBL: 86/77\                                 
                                                                                                              LCX: 101/92\    MBL: 23/25                                  
                                                                                                              RAC: 77/88                                                  

                                                                                                                                                                          

  WANG X 2016     128 (64/64)        65.8 (4.4)/65.3 (4.2)          E: 49/15\         NR                      NR              SBL: 26/25\       NR                        *⟪*Practice of internal medicine*⟫*
                                                                    C: 48/16                                                  DBL: 23/22\                                 
                                                                                                                              MBL: 16/17                                  

  ZHOU W 2015     100 (50/50)        69.08 (7.46)/69.46 (7.35)      E: 28/22\         HTN: 23/24\             NR              NR                NR                        2009: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and ACC/AHA/SCAI guidelines on percutaneous coronary intervention.
                                                                    C: 27/23          DM: 9/10\                                                                           
                                                                                      Hyperlipidemia: 20/19                                                               

                                                                                                                                                                          

  PENG WD 2015    64 (32/32)         61.5 (5.5)/60.5 (5.8)          E: 19/13\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 18/14                                                                                              

                                                                                                                                                                          

  ZHANG Y 2015    80 (40/40)         53.2 (5.4)/51.9 (5.3)          E: 21/19\         NR                      NR              NR                NR                        CA
                                                                    C: 22/18                                                                                              

                                                                                                                                                                          

  WANG K 2015     148 (75/73)        57.6 (10.3)/56.5 (9.1)         E: 59/16\         HTN: 32/34\             NR              NR                NR                        CA
                                                                    C: 56/19          DM: 23/28\                                                                          
                                                                                      Hyperlipidemia: 55/45                                                               

                                                                                                                                                                          

  LU HW 2014      180 (90/90)        60.2 (6.9)/61.8 (7.2)          E: 48/42\         HTN: 59/53\             NR              SBL: 36/32\       132/127                   Nomenclature and diagnostic criteria of Ischemic heart disease (WHO), 2009: Guideline for Percutaneous Coronary Intervention (CSC)
                                                                    C: 46/44          DM: 23/25\                              DBL: 33/40\                                 
                                                                                      Hyperlipidemia: 13/17                   TBL: 21/18                                  

                                                                                                                                                                          

  ZHANG PF 2014   123 (61/62)        57.44 (8.07)/60.64 (8.91)      E: 39/22\         NR                      NR              NR                NR                        CA
                                                                    C: 38/24                                                                                              

                                                                                                                                                                          

  SHI QJ 2014     60 (30/30)         60.3 (6.2)/62.8 (6.2)          E: 20/10\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 18/12                                                                                              

                                                                                                                                                                          

  CHEN K 2014     80 (40/40)         56.2 (5.2)/57.9 (5.3)          E: 19/21\         NR                      NR              NR                NR                        CA
                                                                    C: 20/20                                                                                              

  LI B 2014       102 (51/51)        61.2 (5.8)/60.6 (5.8)          E: 38/17\         HTN: 22/24\             NR              NR                77/81                     CA
                                                                    C: 36/19          DM: 10/11\                                                                          
                                                                                      Hyperlipidemia: 30/25                                                               

                                                                                                                                                                          

  LI CW 2014      83 (43/40)         53.14 (9.45)/54.19 (10.7)      E: 27/16\         NR                      NR              NR                NR                        2007: Guideline for Percutaneous Coronary Intervention (CSC)
                                                                    C: 22/18                                                                                              

                                                                                                                                                                          

  WANG ZQ 2013    100 (50/50)        56.92 (12.21)/58.90 (13.19)    E:28/22\          HTN: 14/16\             NR              SBL: 12/10        NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C:27/23           DM: 8/9\                                                                            
                                                                                      Hyperlipidemia: 12/11                                                               

                                                                                                                                                                          

  ZHANG Q 2013    1123 (509/514)     55.6 ± 7.9/55.5 ± 7.8          E: 438/71\        HTN: 274/29\            NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 441/73         DM: 139/127\                                                                        
                                                                                      Stroke: 3/26                                                                        

                                                                                                                                                                          

  DENG XD 2013    62 (31/30)         59.0 (42\~76)/59.5 (41\~78)    E: 21/10\         NR                      LAD: 20/18\     NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 20/10                                  LCX: 2/1\                                                   
                                                                                                              RAC: 9/11                                                   

                                                                                                                                                                          

  CHEN K 2013     60 (30/30)         55.2 (5.2)/54.9 (5.3)          E: 16/14\         NR                      NR              NR                NR                        CA
                                                                    C: 15/15                                                                                              

                                                                                                                                                                          

  SI XC 2013      120 (60/60)        NR                             NR                NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)

                                                                                                                                                                          

  HAN P 2012      102 (54/48)        NR                             NR                NR                      NR              NR                NR                        CA

                                                                                                                                                                          

  REN XY 2012     68 (35/33)         56.2 (5.3)/55.9 (5.8)          E: 18/17\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 17/16                                                                                              

                                                                                                                                                                          

  NIU XY 2012     71 (41/30)         60.5 (6.50)/61.8 (6.1)         E: 25/16\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 18/12                                                                                              

                                                                                                                                                                          

  GAO XX 2012     60 (30/30)         56.5 (5.3)/55.9 (5.8)          E: 16/14\         HTN: 9/11\              NR              NR                NR                        CA
                                                                    C: 15/15          DM: 11/10                                                                           

  DAI GF 2011     61 (31/30)         61.3 (7.23)/63.5 (6.1)         E: 19/12\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO) 1979
                                                                    C: 17/13                                                                                              

                                                                                                                                                                          

  MEI CL 2011     124 (61/63)        56.3 (5.6)/58.3 (6.1)          E: 35/26\         DM: 16/17\              NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 36/27          HTN: 20/23                                                                          

                                                                                                                                                                          

  WANG XD 2010    132 (68/64)        65.2 (9.9)/65.1 (10.4)         T: 43/25\         HTN: 59/61\             LAD: 36/34\     SBL: 32/26\       131/126                   CA
                                                                    C: 45/19          DM: 68/64\              LCX: 33/26\     DBL: 34/35\                                 
                                                                                      Hyperlipidemia: 52/49   RAC: 26/28      TBL: 2/3                                    

                                                                                                                                                                          

  CHENG SJ 2010   60 (30/30)         57.9 (5.2)/58.1 (3.9)          T: 20/10\         HTN: 16/13\             NR              SBL: 19/23\       NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 22/8           DM: 6/9\                                MBL: 11/7                                   
                                                                                      hyperlipidemia: 12/11                                                               

                                                                                                                                                                          

  DAI GF 2010     94 (49/45)         61.2 (6.3)/63.8 (5.9)          T: 38/21\         NR                      NR              NR                NR                        Nomenclature and diagnostic criteria of Ischemic heart disease (WHO)
                                                                    C: 26/20                                                                                              

                                                                                                                                                                          

  LIU LL 2010     60 (30/30)         63.57 (50\~75)/62.8 (50\~68)   T: 19/11\         HTN: 22/19\             NR              NR                NR                        2007: Guideline for Percutaneous Coronary Intervention (CSC)
                                                                    C: 18/12          DM: 12/14\                                                                          
                                                                                      Hyperlipidemia: 5/6                                                                 
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EG = experimental group; CG = control group; SD = standard deviation; M/F = male/female; N = number of subjects; CAD = coronary artery disease; HTN = hypertension; DM = diabetes mellitus; LMCA = left main coronary artery; LAD = left anterior descending coronary; LCX = left circumflex; RAC = right coronary artery; DBL = double branch Lesions; TBL = three branch Lesions; MBL = multiple branch lesions; CA = coronary angiography; NR = not reported; CSC = Chinese Society of Cardiology; WHO = World Health Organization; SBL: Single branch Lesion; ACC = American College of Cardiology; AHA = American Heart Association; SCAI, Society for Cardiovascular Angiography and Interventions.

###### 

Descriptive summary of treatment parameters of included studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author,\                         Intervention   Treatment course (mos)                                                 Follow-up (mos)                                                                                        outcomes        
  year                                                                                                                                                                                                                                          
  -------------------------------- -------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ---------- ---- ----------------------------------
  DAI GF\                          RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1g qd,\                      RWM plus Tongmai decoction P.O. 100 ml bid                                                             6          6    ISR,\
  2017                                            Atorvastatin P.O. 20 mg qd.                                                                                                                                                                   Response rate of ECG

                                                                                                                                                                                                                                                

  ZHANG\                           RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1 g qd,\                     RWM plus Huoxue Tongluo capsule P.O. 4 pills tid                                                       6          6    ISR,\
  RZ 2017                                         Atorvastatin P.O. 20 mg qd.                                                                                                                                                                   Response rate of ECG

                                                                                                                                                                                                                                                

  WANG KL 2016                     RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1 g qd,\                     RWM plus Huxinkang tablets P.O. 10 pills tid                                                           6          6    ISR,\
                                                  Metoprolol tartrate P.O. 12.5 mg bid, Atorvastatin P.O. 10 mg qd.                                                                                                                             Response rate of ECG

                                                                                                                                                                                                                                                

  GONG XY 2016                     RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 100 mg qd.                     RWM plus Huoxue tongmai decoction P.O. 150 ml bid                                                      6          6    ISR

                                                                                                                                                                                                                                                

  TANG YY 2016                     RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1 g qd.                      RWM plus Yiqi tongluo huatan decoction P.O. 1 dose bid                                                 6          6    ISR

                                                                                                                                                                                                                                                

  ZHOU JC 2016                     RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1g qd,\                      RWM plus Qiwei sanxiong decoction P.O. 1/2 dose bid                                                    6          6    ISR
                                                  Atorvastatin P.O. 20 mg qd.                                                                                                                                                                   

                                                                                                                                                                                                                                                

  ZHU HB\                          RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.5 g qd,\                     RWM plus Mailuotong capsule P.O. 0.84 g tid.                                                           6          6    ISR,\
  2016                                            Metoprolol tartrate P.O. 75 mg qd, Atorvastatin P.O. 10 mg qd.                                                                                                                                Response rate of ECG

                                                                                                                                                                                                                                                

  XIAO\                            RWM:           Aspirin, Clopidogrel, ACEI/ARB, Beta blocker,\                         RWM plus Xinxuetong capsule P.O. 2 pills tid.                                                          6          6    ISR
  NH 2016                                         Rosuvastatin P.O. 10 mg qd,                                                                                                                                                                   

  Plus placebo P.O. 2 pills tid.                                                                                                                                                                                                                

                                                                                                                                                                                                                                                

  REN DD\                          RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1 g qd,\                     RWM plus Huoxue tongmai decoction P.O. 200 ml bid.                                                     6          6    ISR
  2016                                            Metoprolol tartrate P.O. 25 mg bid, Rosuvastatin P.O. 10 mg qd.                                                                                                                               

  LI QZ\                           RWM:           Clopidogrel P.O.75 mg qd, Aspirin P.O. 100 mg qd,\                     RWM plus Guanxin tongluo capsule P.O. 1.6 g tid                                                        6          6    ISR,\
  2016                                            Atorvastatin P.O. 10 mg qd.                                                                                                                                                                   Response rate of ECG

                                                                                                                                                                                                                                                

  SUN QY\                          RWM:           Aspirin P.O. 100 mg qd, Benazepril hydrochloride P.O. 10 mg qd,\       RWM plus Yixin tongmai decoction P.O. 1/2 dose bid.                                                    6          6    ISR
  2016                                            Clopidogrel P.O. 75 mg qd, Isosorbide mononitrate P.O. 25 mg tid,\                                                                                                                            
                                                  Metoprolol tartrate P.O. 12.5 mg bid, Simvastatin P.O. 10 mg qd.                                                                                                                              

                                                                                                                                                                                                                                                

  XU MT 2016                       RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1 g qd,\                     RWM plus Guanxin suhe wan P.O. 30 g tid.                                                               6          6    ISR
                                                  Atorvastatin P.O. 10 mg qd                                                                                                                                                                    

                                                                                                                                                                                                                                                

  MENG XL 2016                     RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1 g qd,\                     RWM plus Yiqi Huoxue Jiedu decoction P.O. 300 ml bid.                                                  6          6    ISR,\
                                                  Atorvastatin P.O. 20 mg qd, Valsartan P.O. 80 mg qd,\                                                                                                                                         Angina recurrence
                                                  Metformin P.O. 0.5 g bid.                                                                                                                                                                     

                                                                                                                                                                                                                                                

  YANG TL 2016                     RWM:           Aspirin P.O. 100 mg qd, Clopidogrel P.O. 75 mg qd,\                    RWM plus Tongxinluo capsule P.O. 1.04 g tid.                                                           12         12   ISR, CD,\
                                                  pioglitazone 30 mg/d, ACEI/ARB, Beta blocker, Statins.                                                                                                                                        Angina recurrence,\
                                                                                                                                                                                                                                                MI, MLD, LLL

  plus placebo P.O. 1.04 g tid.                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                

  WANG X 2016                      RWM:           Aspirin P.O.100 mg qd, Clopidogrel P.O. 75 mg qd,\                     RWM plus Huoxue yiqi tongmai decoction 100 ml bid.                                                     6          6    ISR,\
                                                  Atorvastatin P.O. 20 mg qd, Isosorbide mononitrate P.O. 40 mg qd,\                                                                                                                            MI, PCI, MLD,\
                                                  Metoprolol P.O. 23.75 mg qd.                                                                                                                                                                  Angina recurrence

                                                                                                                                                                                                                                                

  ZHOU W 2015                      RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O.0.1 g qd,\                      RWM plus Longzhi dispensing granules P.O. 36 g tid.                                                    6          6    ISR
                                                  Simvastatin P.O. 20 mg qd, Glyceryl trinitrate P.O. 0.5 mg prn.                                                                                                                               

  PENG WD 2015                     RWM:           Clopidogrel P.O. 75 mg qd,\                                            RWM plus Mailuo shutong capsule P.O. 0.84 g tid                                                        6          6    ISR,\
                                                  Aspirin P.O. 0.5 g qd,\                                                                                                                                                                       Response rate of ECG
                                                  Atorvastatin P.O. 10 mg qd,\                                                                                                                                                                  
                                                  Metoprolol tartrate P.O. 75 mg qd.                                                                                                                                                            

                                                                                                                                                                                                                                                

  ZHANG Y 2015                     RWM:           Aspirin, Clopidogrel, Nitrates, ACEI, Beta blocker, Statins.           RWM plus No. 1 Xintong prescription P.O. 100 ml bid.                                                   6          6    ISR

                                                                                                                                                                                                                                                

  WANG K 2015                      RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 100 mg qd,\                    RWM plus Xuefu zhuyu capsule P.O. 3 pills tid.                                                         12         12   ISR, CD,\
                                                  Atorvastatin P.O. 40 mg qd, Metoprolo P.O. 25 mg qd.                                                                                                                                          Angina recurrence

                                                                                                                                                                                                                                                

  LU HW 2014                       RWM:           Aspirin, Clopidogrel, Nitrates, ACEI, Beta blocker, Statins, CCB.      RWM plus Tongxinluo capsule P.O. 3 pills tid.                                                          12         12   ISR, CD, MI, LLL,\
                                                                                                                                                                                                                                                Angina recurrence

                                                                                                                                                                                                                                                

  ZHANG PF 2014                    RWM:           Clopidogrel P.O. 75 mg qd, Atorvastatin P.O. 20 mg qd,\                RWM plus Xinmai futong decoction P.O. 1/2 dose bid.                                                    6          6    ISR, LLL, Angina recurrence
                                                  Metoprolol tartrate P.O. 12.5 mg bid.                                                                                                                                                         

                                                                                                                                                                                                                                                

  SHI QJ 2014                      RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O. 0.1 g qd,\                     RWM plus Yiqi huayu jiedu decoction P.O. 1/2 dose bid.                                                 6          6    ISR,\
                                                  Atorvastatin P.O. 20 mg qd.                                                                                                                                                                   Response rate of ECG

                                                                                                                                                                                                                                                

  CHEN K 2014                      RWM:           Aspirin, Clopidogrel, Statins, ACEI, Beta blocker, nitrates, CCB.      RWM plus No. 2 Xintong prescription P.O. 200 ml bid.                                                   6          6    ISR

                                                                                                                                                                                                                                                

  LI B\                            RWM:           Aspirin, Clopidogrel, Nitrates, Beta blockers, Statins.                RWM plus Qishen yiqi droplets P.O. 0.5 tid.                                                            6          6    ISR, Angina recurrence,\
  2014                                                                                                                                                                                                                                          Response rate of ECG

                                                                                                                                                                                                                                                

  LI CW\                           RWM                                                                                   RWM plus Qishen yiqi droplets P.O. 0.5 tid.                                                            9          9    ISR
  2014                                                                                                                                                                                                                                          

  WANG ZQ 2013                     RWM:           Aspirin P.O.0.1 g qd, Clopidogrel P.O. 75 mg qd,\                      RWM plus Qiwei sanxiong decotion P.O. 150 ml bid.                                                      6          6    ISR,\
                                                  Atorvastatin P.O. 20 mg qd.                                                                                                                                                                   Angina recurrence

                                                                                                                                                                                                                                                

  ZHANG Q 2013                     RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O.0.1 g qd,\                      RWM plus Shenshao oral lotion P.O. 10 ml tid.                                                          12         12   ISR,\
                                                  Atorvastatin P.O. 20 mg qd.                                                                                                                                                                   MLD, LLL

                                                                                                                                                                                                                                                

  DENG XD 2013                     RWM:           Aspirin P.O.300 mg/d, Clopidogrel P.O. 75 mg/d.                        RWM plus Tongxinluo capsule P.O. 4 pills tid                                                           6          6    ISR,\
                                                                                                                                                                                                                                                MLD

                                                                                                                                                                                                                                                

  CHEN K 2013                      RWM:           Aspirin, Clopidogrel, Statins, ACEI, Beta blockers, Nitrates, CCB.     RWM plus No. 3 Xintong prescription P.O. 100 ml bid.                                                   12         12   ISR

                                                                                                                                                                                                                                                

  SI XC 2013                       RWM                                                                                   RWM plus Shexiang baoxin wan P.O. 2 pills tid.                                                         6          18   ISR, CD, MI, Angina recurrence,\
                                                                                                                                                                                                                                                Revascularization

                                                                                                                                                                                                                                                

  HAN P 2012                       RWM:           Aspirin P.O. 300 mg (0--3 m),75--150 mg qd (3--6 m)\                   RWM plus combined decoction (Gualou xiebai banxia decoction, Xuefu zhuyu decoction) P.O. 100 ml bid.   6          6    ISR
                                                  Clopidogrel P.O. 75 mg qd.                                                                                                                                                                    

                                                                                                                                                                                                                                                

  REN XY 2012                      RWM:           Aspirin, Clopidogrel, nitrate, Statins, ACEI.                          RWM plus Yiqi huayu decoction P.O. 100 ml bid.                                                         6          6    ISR

                                                                                                                                                                                                                                                

  NIU XY 2012                      RWM                                                                                   RWM plus Jingqi danshen decoction P.O. 97 g bid.                                                       3          6    ISR\
                                                                                                                                                                                                                                                Response rate of ECG

                                                                                                                                                                                                                                                

  GAO XX 2012                      RWM:           Aspirin, Clopidogrel, Statins.                                         RWM plus No. 1 Xintong prescription P.O. 100 ml bid.                                                   6          6    ISR

  DAI GF 2011                      RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O.0.1 g qd,\                      RWM plus Tongxinluo capsule P.O.                                                                       6          6    ISR,\
                                                  Atorvastatin P.O. 20 mg qd.                                                                                                                                                                   Response rate of ECG

                                                                                                                                                                                                                                                

  MEI CL 2011                      RWM:           Clopidogrel P.O. 75 mg qd, Aspirin P.O.0.1 g qd,\                      RWM plus Xueyu decoction P.O. 100 ml bid.                                                              3          6    ISR,\
                                                  Simvastatin P.O. 20 mg qd.                                                                                                                                                                    Angina recurrence

                                                                                                                                                                                                                                                

  WANG XD 2010                     RWM:           Aspirin P.O. 300 mg (0-1m), 100 mg (1--12 m) qd,\                      RWM plus Tongxinluo capsule P.O. 1.14 g tid.                                                           12         12   ISR,\
                                                  Clopidogrel P.O. 75 mg qd, Atorvastatin P.O. 20 mg qd.                                                                                                                                        Angina recurrence,\
                                                                                                                                                                                                                                                MI, CD, MLD

  Plus placebo P.O. 1.14g tid.                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                

  CHENG SJ 2010                    RWM:           Aspirin, Clopidogrel, Glyceryl trinitrate, Metoprolol, Atorvastatin.   RWM plus Anxin granules P.O. 3.5 g tid.                                                                6          6    ISR, MI, PCI

                                                                                                                                                                                                                                                

  DAI GF 2010                      RWM:           Clopidogrel P.O. 75 mg qd, Atorvastatin P.O. 20 mg qd.\                RWM plus Yiqi huoxue tongmai decoction P.O. 250 ml bid.                                                12         12   ISR,\
                                                  Aspirin P.O. 100 mg qd,\                                                                                                                                                                      Response rate of ECG

                                                                                                                                                                                                                                                

  LIU LL 2010                      RWM:           Clopidogrel P.O. 75 mg qd, Atorvastatin P.O. 20 mg qd.\                RWM plus Jingtian zaitong capsule P.O. 10 g tid.                                                       6          6    ISR,\
                                                  Aspirin P.O. 100 mg qd,\                                                                                                                                                                      Response rate of ECG
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EG = experimental group; CG = control group; RWM = routine western medicine; ECG = electrocardiogram; ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blockage; CD = cardiac death; MI = myocardial Infarction; MLD = minimum lumen diameter; LLL = late loss of lumen; PCI = percutaneous coronary intervention; CCB = calcium channel blocker.

###### 

Quality of the included RCTs as assessed by the Cochrane risk of bias assessment.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Quality assessment criteria              DAI GF\   CHEN K2013   CHEN K2014   CHENG SJ2010   DAI GF\   DAI GF\   DENG XD2013   GAO XX2012   GONG XY2016   HAN P2012   LI B2014   LI CW\   LI QZ\   LIU LL\
                                           2017                                               2010      2011                                                                      2014     2016     2010
  ---------------------------------------- --------- ------------ ------------ -------------- --------- --------- ------------- ------------ ------------- ----------- ---------- -------- -------- ---------
  Random sequence generation               \+        \-           \-           \+             \-        \-        \-            \-           \+            \-          \-         \-       \-       \+

  Allocation concealment                   \-        \-           \-           \-             \-        \-        \-            \-           \-            \-          \-         \+       \-       \-

  Blinding of participants and personnel   \+        \+           \+           \+             \+        \+        \+            \+           \+            \+          \+         \+       \+       \+

  Blinding of outcome assessment           \+        \+           \+           \+             \+        \+        \+            \+           \+            \+          \+         \+       \+       \+

  Incomplete outcome data                  \-        \+           \+           \+             \+        \+        \+            \+           \+            \-          \-         \-       \+       \+

  Selective reporting                      \+        \+           \+           \+             \+        \+        \-            \+           \+            \+          \+         \+       \+       \+

  Other bias                               \+        \+           \+           \+             \+        \+        \+            \+           \+            \+          \+         \+       \+       \+

  Overall quality score (maximum = 7)      5         5            5            6              5         5         4             5            6             4           4          5        5        6
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Quality assessment criteria              LU HW\   MEI CL\   MENG XL2016   NIU XY2012   PENG WD2015   REN DD2016   REN XY2012   SHI QJ2014   SI XC\   SUN QY2016   TANG YY2016   WANG K2015   WANG KL2016
                                           2014     2011                                                                                      2013                                             
  ---------------------------------------- -------- --------- ------------- ------------ ------------- ------------ ------------ ------------ -------- ------------ ------------- ------------ -------------
  Random sequence generation               \+       \-        \-            \+           \-            \+           \-           \+           \-       \+           \-            \-           \+

  Allocation concealment                   \-       \-        \-            \-           \-            \-           \-           \-           \-       \-           \-            \-           \-

  Blinding of participants and personnel   \+       \+        \+            \+           \+            \+           \+           \+           \+       \+           \+            \+           \+

  Blinding of outcome assessment           \+       \+        \+            \+           \+            \+           \+           \+           \+       \+           \+            \+           \+

  Incomplete outcome data                  \+       \+        \+            \+           \+            \+           \+           \+           \+       \+           \+            \-           \+

  Selective reporting                      \+       \+        \+            \+           \+            \+           \+           \+           \+       \+           \+            \+           \+

  Other bias                               \+       \+        \+            \+           \+            \+           \+           \+           \+       \+           \+            \+           \+

  Overall quality score (maximum = 7)      6        5         5             6            5             6            5            6            5        6            5             4            6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  Quality assessment criteria              WANG X2016   WANG XD2010   WANG ZQ2013   XIAO NH2016   XU MT2016   YANG TL2016   ZHANG PF2014   ZHANG Q2013   ZHANG RZ2017   ZHANG Y2015   ZHOU JC2016   ZHOU W2015   ZHU HB2016
  ---------------------------------------- ------------ ------------- ------------- ------------- ----------- ------------- -------------- ------------- -------------- ------------- ------------- ------------ ------------
  Random sequence generation               \+           \-            \+            \-            \-          \-            \-             \-            \-             \-            \-            \+           \-
  Allocation concealment                   \-           \-            \-            \-            \-          \-            \-             \-            \-             \-            \-            \-           \-
  Blinding of participants and personnel   \+           \+            \+            \+            \+          \+            \+             \+            \+             \+            \+            \+           \+
  Blinding of outcome assessment           \+           \+            \+            \+            \+          \+            \+             \+            \+             \+            \+            \+           \+
  Incomplete outcome data                  \+           \+            \+            \+            \+          \+            \+             \-            \+             \+            \+            \-           \+
  Selective reporting                      \+           \+            \+            \+            \+          \+            \+             \+            \+             \+            \+            \+           \+
  Other bias                               \+           \+            \+            \+            \+          \+            \+             \+            \+             \+            \+            \+           \+
  Overall quality score (maximum = 7)      6            5             6             5             5           5             5              4             5              5             5             5            5

###### 

Egger\'s test.

  Std_Eff   Coef.       Std. Err.   *t*     *P* \> \|*t*\|   \[95% Conf. Interval\]   
  --------- ----------- ----------- ------- ---------------- ------------------------ ----------
  slope     −.192833    .1590705    −1.21   0.234            −0.5168491               .1311831
  bias      −1.155985   .3911951    −3.97   0.000            −1.74913                 −.56284

###### 

Subgroup analysis of CCM plus RWM versus RWM in cases of ISR.

  RWM                                                       Studies (*n*)   RR (95% CI)           *I* ^2^
  --------------------------------------------------------- --------------- --------------------- ---------
  DAPT                                                      4               0.32 \[0.18, 0.57\]   0%
  DAPT + Statin                                             13              0.45 \[0.32, 0.64\]   0%
  DAPT + *β*-blocker + Statin                               4               0.36 \[0.20, 0.64\]   0%
  DAPT + ACEI/ARB + Statin + Metformin                      1                                      
  Nitrates + DAPT + Statin                                  2               0.36 \[0.12, 1.08\]   0%
  Nitrates + DAPT + ACEI/ARB + Statin                       1                                      
  Nitrates + DAPT + *β*-blocker + Statin                    2               0.58 \[0.24, 1.42\]   0%
  Nitrates + DAPT + ACEI/ARB + *β*-blocker + Statin         2               0.39 \[0.21, 0.70\]   70%
  Nitrates + DAPT + ACEI/ARB + *β*-blocker + Statin + CCB   2               0.57 \[0.37, 0.86\]   0%
  Unclear                                                   3                                      

###### 

Subgroup analysis of CCM plus RWM versus RWM in cases of ISR.

  CCM         Studies (*n*)   RR (95% CI)           *I* ^2^
  ----------- --------------- --------------------- ---------
  decoction   18              0.35 \[0.26, 0.46\]   0%
  granules    2               0.39 \[0.13, 1.21\]   0%
  pills       3               0.59 \[0.34, 1.01\]   0%
  capsules    9               0.49 \[0.36, 0.67\]   0%
  tablets     1                                      

###### 

Effect of CCM plus RWM versus RWM on Adverse Reactions.

  Study          Intervention                                EG   CG    RR \[95% CI\]         
  -------------- ------------------------------------------- ---- ----- --------------- ----- ----------------------
  WANG X 2016    Huoxue yiqi decoction plus RWM versus RWM   8    64    5               64    1.60 \[0.55, 4.63\]
  ZHANG Q 2013   Shenshao Oral Lotion plus RWM versus RWM    2    473   1               477   2.02 \[0.18, 22.17\]

EG = experimental group; CG = control group; EE = events.

###### 

Effect of CCM plus RWM versus RWM on MACE after PCI.

  --------------------------------------------------------------------------------------------------------
  MACE                                        No. of studies/patients   Follow-up\   Pooled estimate\
                                                                        (mos.)       (RR, 95% CI)
  ------------------------------------------- ------------------------- ------------ ---------------------
  Revascularization\                          3/308                     6--18        0.33 \[0.07, 1.62\]
  (CCM plus RWM versus RWM)                                                          

  Myocardial Infarction\                      3/308                     6--18        0.33 \[0.17, 1.62\]
  (CCM plus RWM versus RWM)                                                          

  Myocardial Infarction\                      2/475                     6            0.42 \[0.11, 1.60\]
  (CCM plus RWM versus CM placebo plus RWM)                                          

  Cardiac Mortality\                          5/921                     12--18       0.25 \[0.03, 2.21\]
  (CCM plus RWM versus RWM)                                                          

  Recurrent Angina\                           9/1095                    6--18        0.50 \[0.38, 0.65\]
  (CCM plus RWM versus RWM)                                                          

  Recurrent Angina\                           2/475                     6            0.32 \[0.19, 0.54\]
  (CCM plus RWM versus CM placebo plus RWM)                                          
  --------------------------------------------------------------------------------------------------------

###### 

Effect of CCM on MLD.

  Study           Intervention                                             EG     CG     MD \[95% CI\]                       
  --------------- -------------------------------------------------------- ------ ------ --------------- ------ ------ ----- -----------------------
  DENG XD 2013    Tongxinluo capsule plus RWM versus RWM                   3.97   0.59   31              5.58   0.67   30    −1.61 \[−1.93, 1.29\]
  WANG X 2016     Huoxue yiqi tongmai decoction plus RWM vs RWM            2.02   0.22   64              1.6    0.2    64    0.42 \[0.35, 0.49\]
  WANG XD 2010    Tongxinluo capsule plus RWM versus CM placebo plus RWM   2.43   0.62   68              1.16   0.87   64    1.27 \[1.01, 1.53\]
  YANGN TL 2016   Tongxinluo capsule plus RWM versus CM placebo plus RWM   2.81   0.41   172             2.46   0.37   171   0.35 \[0.27, 0.43\]
  ZHANG Q 2013    Shenshao oral lotion plus RWM versus RWM                 2.11   0.38   473             2.09   0.32   477   0.02 \[−0.02, 0.06\]

EG = experimental group; CG = control group; MD = mean difference.

###### 

Effect of CCM on LLL.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Study           Intervention                                             EG     CG     MD \[95% CI\]                       
  --------------- -------------------------------------------------------- ------ ------ --------------- ------ ------ ----- -----------------------
  LU HW\          Tongxinluo capsule plus RWM versus RWM                   0.43   0.17   90              0.79   0.24   90    −0.36 \[−0.42, 0.30\]
  2014                                                                                                                       

  YANGN TL 2016   Tongxinluo capsule plus RWM versus CM placebo plus RWM   0.21   0.17   172             0.45   0.24   171   −0.24 \[−0.28, 0.20\]

  ZHANG PF 2014   Xinmai futong decoction plus RWM versus RWM              0.5    0.21   61              0.8    0.4    62    −0.30 \[−0.41, 0.19\]

  ZHANG Q 2013    Shenshao oral lotion plus RWM versus RWM                 0.62   0.3    473             0.67   0.32   477   −0.05 \[−0.09, 0.01\]
  --------------------------------------------------------------------------------------------------------------------------------------------------

EG = experimental group; CG = control group; MD = mean difference.

[^1]: Academic Editor: Kieran Cooley
